Accueil   Diary - News   All news Biom’up granted FDA IDE approval for HEMOSNOW

Biom’up granted FDA IDE approval for HEMOSNOW

 

 

Saint-Priest, France, April 24, 2019 - 8h00 (CET) - Biom’up (the « Company »), specializing in surgical hemostasis, announced today that the U.S. Food and Drug Administration (FDA) approved the IDE (Investigational Device Exemption) application for HEMOSNOW, a hemostatic dry powder made from porcine collagen and bovine-derived chondroitin sulfate developed by the Company for managing minimal and mild levels of bleeding during surgical procedures. The Company initially submitted the IDE application to FDA for HEMOSNOW in January 2019.

 

Read the press release

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close